European Commission: Horizon 2020
|
Funding Scheme
|
Call Opens
15 March 2016 |
Deadline
27 April 2016 |
Proposal Type
Full Proposal |
Eligibility Criteria
European Union. Taking into consideration that, according to PAHO/WHO, Brazil is the country most severely affected by ZIKV, legal entities established in Brazil are eligible for funding.
|
Description of Call
The objective is to establish a multinational and multidisciplinary consortium across Latin America and other affected or at risk regions, able to implement the urgently needed research during the ongoing ZIKV outbreak.
- The evaluation of the potentially causative relationship between ZIKV and the severe reported complications, as well as the exploration of the mechanisms involved or of alternative aetiologies if needed.
- If such an association is confirmed, the consortium should be ready to rapidly launch additional studies
- The consortium should further capitalise on the platforms established and the experience gained through this urgent ZIKV research response, in order to evolve into a network capable of rapidly launching a research response to future severe infectious outbreaks caused by emerging pathogens with pandemic potential or potential to cause significant damage to health and socio-economics
If more than one proposal is successful, proposals should collaborate and this should be indicated in the proposal.
|
UK Department of Health, Small Business Research Initiative (SBRI)
|
Funding Scheme
New vaccines for global epidemics – development and manufacture |
Call Opens
29 February 2016 |
Deadline
04 May 2016 |
Proposal Type
Full Proposal |
Eligibility Criteria
The competition is open to all organisations that can demonstrate that their product or work has a realistic route to market, whether in the short or long term. Successful organisations will attract a 100% funded development contract.
This competition is wholly funded by Official Development Assistance (ODA). This means that while work on projects can be carried out in high-income countries, there must be a clear explanation of how the research/project will benefit those in low-income countries.
|
Description of Call
The Department of Health is to invest up to £10 million in two competition streams in line with the priorities identified by the UK Vaccine Network.
This competition will support projects seeking to develop vaccines, vaccine platform technologies and manufacturing technologies that will enable an effective, rapid response during future outbreaks of the following pathogens: Chikungunya, Crimean-Congo Haemorrhagic Fever, Dengue Virus, Ebola, Hantavirus, Lassa, Marburg, Middle East Respiratory Syndrome, Nipah, Plague, Q Fever, Rift Valley Fever and Zika.
In stream 1 up to £6 million is available for exploring scientific and technical feasibility.
In stream 2 up to £4 million is available to projects at a more advanced stage of development.
|
US National Institutes for Health (NIH)
|
Funding Scheme
Rapid Assessment of Zika Virus (ZIKV) Complications (R21) |
Call Opens
20 March 2016 |
Deadline
30 April 2016 |
Proposal Type
Rapid Application - Full Proposal |
Eligibility Criteria
US and non-US Higher education institutions, governments, for-profit, non-profit and other organisations. |
Description of Call
The R21 activity code is intended to encourage new exploratory and developmental research projects. For example, such projects could assess the feasibility of a novel area of investigation or a new experimental system that has the potential to enhance health-related research. Another example could include the unique and innovative use of an existing methodology to explore a new scientific area. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research.
The participating NIH institutes are issuing this FOA using an expedited (rapid) mechanism given the urgent need to determine whether ZIKV infection causes microcephaly and other congenital abnormalities in babies and the potential rapid spread of ZIKV to the United States. Additionally, research to quantify the risk to the blood supply in affected regions and the potential clinical impact of transfusion-transmission of the Zika virus are urgently needed to inform strategies to reduce or prevent Zika transmission by blood transfusion.
For research areas of high priority, see the call text.
|
US National Institutes for Health (NIH) and National Institute for Allergies and Infectious Diseases (NIAID)
|
Funding Scheme
U19 (Research Program –Cooperative Agreements) – Tropical Medicine Research Centre |
Call published
11 December 2015 |
Deadline
3 May – 3 June 2016 |
Proposal Type
Full Proposal |
Eligibility Criteria
Applicant organizations must be headquartered in foreign (non-U.S.) resource-constrained countries (i.e. low-income economies, lower-middle-income economies, and upper-middle-income economies by World Bank definition). To determine the eligibility status of a country, see the Income group column here |
Description of Call
The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications from institutions/organizations that propose to conduct research on the causes, diagnosis, prevention, and treatment of tropical diseases in endemic areas. The scope of the research to be supported is limited to select Neglected Tropical Diseases (NTDs) and their corresponding vectors. Research may be focused on a single pathogen or more than one pathogen causing NTDs. Multi-disciplinary research and/or study of multiple pathogens is encouraged. This program is not intended to support research which can be conducted primarily in U.S. institutions.
About Tropical Medicine Research Centres |